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Over the past decade, adeno-associated (AAV) virus has emerged as an important vector for gene therapy. As a result, understanding its basic
biology, including intracellular trafficking, has become increasingly important. Here, we describe the effect of inhibiting dynein function or altering
the state of microtubule polymerization on rAAV2 transduction. Overexpression of dynamitin, resulting in a functional inhibition of the minus-end-
directed microtubule motor protein dynein, did not inhibit transduction. Equally, treatment of cells with nocodazole, or concentrations of vinblastine
that result in the disruption of microtubules, had no significant effect on transduction. In contrast, high concentrations of Taxol and vinblastine,
resulting in microtubule stabilization and the formation of tubulin paracrystals respectively, reduced rAAV2 transduction in a vector-dose-dependent
manner. These results demonstrate that AAV2 can infect HeLa cells independently of dynein function or an intact microtubule network.
© 2007 Elsevier Inc. All rights reserved.Keywords: Adeno-associated virus; Microtubule; Dynamitin; Nocodazole; Vinblastine; Taxol; TraffickingIntroduction
Adeno-associated virus (AAV) is a small, non-enveloped,
single-stranded DNA virus of the genus Dependovirus and the
family Parvoviridae. As its name and classification indicate,
AAV depends on a helper virus – which can be either adeno-
virus or herpes simplex virus – for a productive replication. In
their absence, AAV can integrate its genome site specifically
into the human chromosome 19 entering a so-called latent phase
(Kotin et al., 1990; Samulski et al., 1991). Partly as a result of
this unique trait as, well as its non-pathogenic nature,
recombinant AAV has gained increasing attention as a gene
therapy vector over the past decade (Wu et al., 2006). To
develop fully the potential of AAV as a gene transfer vector, an
understanding of its biology is crucial.⁎ Corresponding author. Department of Gene and Cell Medicine, Mount
Sinai School of Medicine, 1 Gustave L. Levy Place, Box 1496, New York,
NY 10029-6514, USA. Fax: +1 212 849 2437.
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doi:10.1016/j.virol.2007.05.009For successful transduction recombinant AAV2 (rAAV2) has
to deliver its DNA to the nucleus. This process begins with the
binding of rAAV2 to its primary receptor heparan sulfate
proteoglycan (Summerford and Samulski, 1998) and one of
several possible co-receptors (Asokan et al., 2006; Kashiwakura
et al., 2005; Qing et al., 1999; Qiu and Brown, 1999; Qiu et al.,
1999, 2000; Summerford et al., 1999). AAV2 is then endo-
cytosed in a dynamin-dependent process (Bartlett et al., 2000;
Duan et al., 1999). After endocytosis, AAV is transported to a
perinuclear region. At present, it is unclear if this transport
occurs while AAV2 is in the endosomal system or after its
escape into the cytoplasm. From the perikaryon, the single-
stranded DNA is then imported into the nucleus either as an
intact viral particle (Hansen et al., 2001; Sonntag et al., 2006;
Xiao et al., 2002) or after capsid disassembly (Lux et al., 2005).
Despite considerable progress in recent years (reviewed in Ding
et al., 2005), many aspects of the viral entry pathway of AAV
remain to be elucidated in detail. In particular, the trafficking
from the cell periphery to a perinuclear region remains incom-
pletely understood.
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has been suggested that viruses and viral nucleocapsids cannot
freely diffuse in the cytoplasm (Dohner and Sodeik, 2005; Luby-
Phelps, 2000), although recent theoretical calculations have
challenged this view for small viruses such as AAV (Dinh et al.,
2005). Instead, several viruses such as adenovirus, herpes virus
and rabies virus (Dohner and Sodeik, 2005) have been shown to
take advantage of the minus-end-directed microtubule motor
protein dynein to deliver their genomes to the perinuclear region.
Interestingly, it has been reported that a relative of AAV,
canine parvovirus (CPV), also utilizes the dynein machinery for
its transport to the perikaryon (Suikkanen et al., 2003; Vihinen-
Ranta et al., 2000). Here we show that, in contrast to CPV,
rAAV2 can transduce cells independently of dynein function
and intact microtubules.
Results
Transport of cargo from the cell periphery towards the cell
center often occurs along microtubules and is mediated by theFig. 1. Overexpression of dynamitin (p50) has no effect on rAAV2 transduction. (
transfected with plasmids encoding mCherry (red) or dynamitin-mCherry (p50-mChe
anti-p230 antibody (Alexa488, green), with the nucleus stained with DAPI (blue). Sc
Twenty-four hours after transfection with plasmids encoding mCherry or dynamitin-m
cell. Another 24 h later, cells gated for a coherent FSC/SSC population (104 cells in thi
FACS. Open bars correspond to cells that were mCherry−, filled bars correspond to c
each population. Error bars represent mean±SD (n=3).minus-end-directed microtubule motor protein dynein. To
analyze if transduction by rAAV2 is dependent on dynein
function we overexpressed dynamitin in the cells to be infected.
Dynamitin is a subunit of the dynactin complex and, if over-
expressed, acts as a dominant-negative inhibitor of dynein func-
tion by disrupting the coupling of cargo and the dynein complex.
Thus, overexpression of dynamitin has been used to demonstrate
dynein mediated intracellular transport of adenovirus and herpes
simplex virus 1 (Dohner et al., 2006; Suomalainen et al., 1999).
To allow us to measure dynamitin expression, we generated an
expression vector encoding for a fusion protein of dynamitin
with the photostable red-fluorescent protein mCherry (Shaner et
al., 2004). A plasmid encoding for mCherry alone served as a
negative control.
In a first step, we confirmed the expression of functional
levels of dynamitin by visualizing the trans-Golgi network
protein p230 (Gleeson et al., 1996) in transfected cells 24 h
post-transfection. As expected (Burkhardt, 1998), non-trans-
fected cells and cells expressing mCherry displayed a classical
perinuclear localization of the Golgi, while the Golgi wasa) Effect of dynamitin overexpression on Golgi organization. HeLa cells were
rry, red). Twenty-four hours after transfection, the Golgi was visualized with an
ale bar=25 μm. (b) Effect of dynamitin overexpression on rAAV2 transduction.
Cherry (p50-mCherry), HeLa cells were infected with rAAV2-GFP at 104 gcp/
s population analyzed) were then analyzed for mCherry and GFP fluorescence by
ells that were mCherry+. Transduction is shown as percent GFP-positive cells in
12 S. Hirosue et al. / Virology 367 (2007) 10–18dispersed throughout the cytoplasm in cells overexpressing
dynamitin-mCherry (Fig. 1a).
We then proceeded to determine the effect of dynamitin
overexpression on AAV transduction. Twenty-four hours after
transfection of HeLa cells with either a plasmid encoding
dynamitin-mCherry or a plasmid encoding mCherry alone, we
added 104 genome containing particles (gcp) per cell of rAAV2
encoding GFP. Twenty-four hours after transduction, mCherry
and GFP expression were analyzed by FACS. As can be seen
from Fig. 1b, no difference in transduction could be detected
between dynamitin-mCherry expressing and non-expressing
cells. These results held true even for cells expressing the
highest level of dynamitin-mCherry (data not shown). Similarly,
overexpression of mCherry alone had no effect on transduction
(Fig. 1b). Furthermore, non-transfected control samples were
transduced to an equal extent. These data indicate that, at least
in HeLa cells, dynein-mediated transport is not mandatory for a
productive transduction with recombinant AAV2. This does not
exclude, however, that dynein-dependent transduction path-
ways exist in addition.Fig. 2. Nocodazole does not inhibit rAAV2 transduction. (a) Microtubule and Golgi m
fixed to observe the microtubule morphology (anti-beta-tubulin, Cy2, green) and
bar=25 μm. (b) Percent GFP+ cells, normalized to no inhibitor control, as a functi
concentrations indicated, HeLa cells were transduced with rAAV2-GFP at 104 gcp/cel
7-amino-actinomycin D (7AAD) prior to FACS analysis for GFP. The GFP+ percenta
by FSC/SSC. The %GFP populations were then normalized to a no inhibitor control
concentrations. Viability was defined as FSC/SSC coherent, 7AAD-population, whiAn alternative way to determine whether transport along
microtubules is important in viral trafficking is the alteration of
the microtubule polymerization state with drugs such as
nocodazole, vinblastine and Taxol.
Treatment of cells with nocodazole results in the disrup-
tion of microtubules (Jordan and Wilson, 1998). Previous
studies analyzing the effect of nocodazole on rAAV2
transduction yielded conflicting results. One study reported
an inhibition of rAAV2 transduction by nocodazole (Sanlio-
glu et al., 2000) while in a different study nocodazole had no
effect (Alexander et al., 1994). In light of these discrepancies,
we decided to study first the effect of nocodazole on rAAV2
transduction.
To this end, we pretreated HeLa cells for 4 h with various
concentrations of nocodazole followed by infection with
104 gcp/cell rAAV2-GFP. After incubation for 24 h in the
continued presence of the drug, we analyzed GFP expression
by FACS analysis. As reported by Alexander and colleagues
(1994), when using low concentrations of nocodazole, we
observed no effect on AAV transduction. Conversely, asorphology. HeLa cells were preincubated in 1 μM nocodazole for 4 h and then
Golgi localization (anti-p230, Cy3, red). Nuclei are in blue (DAPI). Scale
on of nocodazole concentrations. After 4 h preincubation with the nocodazole
l. Twenty-four hours after transduction, the cells were harvested and stained with
ges were determined on the 7AAD-subset of a coherent population first defined
represented by mean±SD. (c) Normalized viability as a function of nocodazole
ch was then normalized to a no inhibitor control.
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inhibition of transduction at higher concentrations of the drug
when we looked at the total population of cells (data not
shown).
However, we also noticed that high concentrations of
nocodazole were very toxic (Fig. 2c) and that – as a result of
the drastic change in morphology caused by the disruption of
microtubules – it is very challenging to determine the viability
of nocodazole treated cells based on the forward/side scatter
(FSC/SSC) profiles alone (Fig. S1a). Hence, we used an
additional criterion for viability namely the exclusion of the
live/dead cell dye 7-amino-actinomycin-D (7AAD). When we
gated on cells that were alive – as determined by both their
FSC/SSC profile and 7AAD exclusion (Fig. S1b) – no inhi-
bition of AAV transduction by nocodazole, even at the highest
concentration tested, was observed (Fig. 2b). Immunofluores-
cence microscopy revealed that in cells treated with
nocodazole the microtubules were disrupted and the Golgi
was, as expected (Burkhardt et al., 1997), dispersed through-
out the cytoplasm (Fig. 2a).
Similar results were obtained with vinblastine, a drug that
at low concentrations disrupts microtubules (Jordan andFig. 3. Vinblastine has a concentration-dependent effect on rAAV2 transduction. Dru
morphology. After 4 h preincubation with 1 μM (left) or 50 μM (right) vinblastine, mi
bar=25 μm. (b) Percent GFP+ cells, normalized to no inhibitor control, as a function o
concentrations.Wilson, 1998) and is less toxic than nocodazole (Fig. 3c).
At concentrations of vinblastine that disrupt the microtubular
network and disperse the Golgi (Fig. 3a, left), no effect on
rAAV2 transduction could be observed (Fig. 3b). Interestingly,
at higher concentrations of vinblastine, which result in the for-
mation of tubulin paracrystals (Manfredi and Horwitz, 1984,
and Fig. 3a, right), vinblastine partially inhibits transduction
(Fig. 3b).
We next wanted to determine if Taxol, a drug known to
stabilize microtubules (Jordan andWilson, 1998), has any effect
on AAV transduction. For this, we pretreated HeLa cells for 4 h
with increasing concentrations of Taxol and analyzed GFP
expression 24 h after addition of 104 gcp/cell rAAV-GFP. Fig.
4b shows that very high concentrations of Taxol were, in
addition to being less toxic than nocodazole (Fig. 4c vs. Fig.
2c), able to inhibit partially AAV2 transduction—even if dead
cells were rigorously excluded. At these concentrations, tubulin
formed randomly initiated bundles at the end of which Golgi
fragments are located (Fig. 4a and Wehland et al., 1983).
It has recently been reported that AAV trafficking is
dependent on the vector dose used (Ding et al., 2006). To test
if the role of microtubules in AAV2 transduction differs atg treatment and analysis was performed as in Fig. 2. (a) Microtubule and Golgi
crotubule morphology and Golgi distribution in HeLa cells were analyzed. Scale
f vinblastine concentrations. (c) Normalized viability as a function of vinblastine
Fig. 4. High concentrations of Taxol partially inhibit rAAV2 transduction. Drug treatment and analysis was performed as in Fig. 2. (a) Microtubule and Golgi
morphology. After 4 h incubation of HeLa cells with 1 μM Taxol, microtubule morphology and Golgi distribution in HeLa cells were analyzed. The cell noted with a
white asterisk is enlarged to show the Golgi location with respect to the microtubules. Scale bar=25 μm. (b) Percent GFP+ cells, normalized to no inhibitor control, as a
function of Taxol concentrations. (c) Normalized viability as a function of Taxol concentrations.
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microtubule-altering drugs at different vector doses. To allow
us to use small viral particle to cell ratios in these experiments,
we took advantage of self-complementary AAV2 preparations
encoding for EGFP. Because transgene expression with these
vectors is not dependent on double-strand synthesis, they
display an earlier onset of transgene expression and transduce
cells more readily (McCarty et al., 2001; Wang et al., 2003).
As can be seen from Fig. 5, the effect of microtubule-altering
drugs is, to a certain degree, dependent on vector dose. At a
particle to cell ratio of 100, the inhibition of transduction by
50 μM Taxol (Fig. 5c, solid bars) or vinblastine (Fig. 5b, solid
bars) was 60% and 69%, respectively. On the other hand, at a
gcp/cell ratio of 1000 the relative reductions were approxi-
mately 45% and at a ratio of 10,000 only about 20% (Figs. 5c
and b, solid bars). At a concentration of 1 μM, Taxol inhibited
transduction as well and again more strongly at lower vector
doses when compared to higher vector doses (Fig. 5c, open
bars). As for single-stranded AAV (104 gcp/cell), high
concentrations of nocodazole (50 μM) had no effect on
AAV2 transduction (Fig. 5a, solid bars), regardless of the
vector dose used. Low concentrations of nocodazole and
vinblastine resulted in a slight inhibition of transduction(b20%) at the lowest vector dose (Figs. 5a and b, open bars).
The significance – if any – of this potential inhibition is
currently unknown. Importantly, however, we never observed
any inhibition at high concentrations of nocodazole supporting
the conclusion that complete disruption of microtubules does
not affect AAV2 transduction. We also observed that the
inhibition of transduction by high concentrations of Taxol and
vinblastine at 104 gcp/cell was lower when we compare
single-stranded and self-complementary virus (compare Figs.
2 and 5). The reason for this is likely that a smaller number of
self-complementary vector particles is needed to result in a
productive transduction because a potential rate-limiting step,
i.e. double-strand synthesis, has been eliminated.
Together, our data show that neither dynein function nor an
intact microtubule network is necessary for a productive
transduction of HeLa cells by rAAV2. On the other hand, the
partial inhibition of transduction by high concentrations of
Taxol and vinblastine suggests that while intact microtubules
are not required for transduction they might nevertheless play a
complex role in rAAV2 transduction. Furthermore, the in-
hibitory effects of high concentrations of Taxol and vinblastine
are vector dose dependent, the inhibition being most pro-
nounced at low gcp/cell ratios. This behavior would be
Fig. 5. Effect of microtubule-altering drugs on AAV2 transduction at various vector doses. Drug treatment and analysis were performed as in Fig. 2. (a) Percent GFP+
cells, normalized to no inhibitor control, as a function of nocodazole concentrations and vector dose. Open bars: 1 μM nocodazole; solid bars: 50 μM nocodazole. The
vector dose indicated is in gcp/cell. (b) Percent GFP+ cells, normalized to no inhibitor control, as a function of vinblastine concentrations and vector dose. Open bars:
1 μM vinblastine; solid bars: 50 μM vinblastine. The vector dose indicated is in gcp/cell. (c) Percent GFP+ cells, normalized to no inhibitor control, as a function of
Taxol concentrations and vector dose. Open bars: 1 μM Taxol; solid bars: 50 μM Taxol. The vector dose indicated is in gcp/cell.
15S. Hirosue et al. / Virology 367 (2007) 10–18consistent with a model of multiple productive pathways for
AAV2 transduction.
Discussion
This study shows that, in contrast to many other viruses,
recombinant AAV2 can transduce HeLa cells in a dynein and
microtubule independent fashion. The cause for the lack of
inhibition of recombinant AAV2 transduction by overexpres-
sion of dynamitin and the reason for the disparate results
obtained when treating cells with nocodazole, vinblastine or
Taxol, respectively, are currently unknown.
It is tempting to speculate, however, that the distinct effects
that these treatments have on the cellular membrane system play
a role in altering the level of AAV transduction. For instance, it
has been shown that overexpression of dynamitin results in
redistribution of lysosomes and late endosomes to the cell
periphery (Burkhardt et al., 1997). Similarly, treatment of CV-1
cells with nocodazole, does not alter the perinuclear localization
of lysosomes (Hamm-Alvarez et al., 1996), incubation with
Taxol, on the other hand, disperses the lysosomes throughout
the cytoplasm (Hamm-Alvarez et al., 1996). In addition to the
endosomal system, other membrane bound compartments are
affected by microtubule-altering drugs and inhibition of dynein
function. For example, the localization of the Golgi is
influenced as well (Burkhardt et al., 1997; Thyberg and
Moskalewski, 1999, and Figs. 1–4a). This is of particular
interest because it has been shown that both AAV2 (Pajusola et
al., 2002) and AAV5 (Bantel-Schaal et al., 2002) can
accumulate in the Golgi.
Because treatment of cells with microtubule-altering drugs
drastically affects most endosomal membrane structures as well
as the Golgi, it is not entirely surprising that immunofluores-cence microscopy with the anti-capsid antibody A20 (Wobus et
al., 2000) failed to show pronounced differences in virus
distribution between untreated cells and cells treated with
different concentrations of inhibitors (data not shown). An in
depth analysis by both light and electron microscopy evaluating
the co-localization of AAV with an array of subcellular markers
will be needed to identify compartments in the endocytic system
that contain AAV and are affected by microtubule-altering
drugs. Because microscopic methods follow bulk virus, it will
be paramount to confirm the involvement of specific compart-
ments in transduction by functional assays, targeting distinct
transport steps.
Recently, it has been reported that AAV2 can bind to the
dynein machinery (Kelkar et al., 2006; Zhao et al., 2006). It
appears therefore surprising that overexpression of dynamitin
and disruption of microtubules with nocodazole or vinblastine
does not result in inhibition of rAAV2 transduction. The sim-
plest explanation for this apparent discrepancy is that both
dynein-mediated as well as microtubule-independent pathways
can result in productive rAAV2 transduction. Such dual modes
of transport are not unprecedented. For instance, it has been
shown that Shiga toxin can be transported to the nucleus by both
microtubule dependent as well as independent mechanisms
(Hehnly et al., 2006). Similarly, the transferrin receptor uses
both microtubule dependent and independent recycling path-
ways (Lakadamyali et al., 2006). Furthermore, recent evidence
that rAAV2 can traffic through either rab7 or rab11-positive
endosomes (Ding et al., 2006) supports the notion that multiple
infectious pathways exist for AAV2.
That the observed inhibition of rAAV2 transduction by high
concentrations of vinblastine and Taxol are due to effects of
these drugs on membrane bound organelles, such as endosomes
or the Golgi, is only one possible explanation. It is also possible
16 S. Hirosue et al. / Virology 367 (2007) 10–18that these drugs affect trafficking of rAAV2 after its escape into
the cytoplasm. It has recently been shown that inclusion of a
peptide into the AAV capsid that binds to the dynein light chain
LC8 increases viral transduction (Xu et al., 2005). This suggests
that, at least in certain cell types, transport of AAV to a
perinuclear region, once it escaped into the cytoplasm, is a
limiting step of transduction.
Clearly, much remains to be learned about the role of
microtubules in AAV transduction. For instance, little is known
on how AAV trafficking differs between cell types as well as
AAV serotypes. Future studies, including light and electron
microscopy and the use of functional assays that target specific
transport modes, will be needed to shed light on the intricate
role that microtubules play in AAV transduction. Understanding
these trafficking patterns of AAV will play an important role in




Nocodazole, Taxol (paclitaxel) and vinblastine sulfate were
purchased from Sigma Aldrich (St. Louis, MO). Stock solutions
were made at 20 mM in cell culture grade dimethylsulfoxide
(DMSO) for nocodazole and Taxol, and in 50% (aq) ethanol for
vinblastine.
Plasmid construction
The plasmid expressing the red-fluorescent protein mCherry
(Shaner et al., 2004) under the control of a CMV promoter, was
generated by replacing EGFP, in the vector pEGFP-N1
(Clontech), with mCherry. To this end, mCherry was amplified
by PCR using the forward and reverse primers, 5′-GGTACCG-
GAT CCTATGGTGA GCAAGGGCGA GGAGGATA-3′ and
5′-GCTTTAGCGG CCGCGTCACC TTACTTGTAC
AGCTCGTCCA TGCCG-3′ and the plasmid pRSET-B-
mCherry (Shaner et al., 2004) as the template. The PCR
product was then cloned into the vector pEGFP-N1 digested
with BamHI and NotI. The plasmid encoding for a dynamitin
(p50)-mCherry fusion protein was generated as described above
except that EGFP was replaced in the vector p50-EGFP
(Palazzo et al., 2001).
Cell culture and virus production
HeLa cells (ATCC, Manassas, VA) were maintained in MEM
Eagle (Mediatech, Herndon, VA), 10% FBS (ATCC), 1:100
dilution of non-essential amino acids (Invitrogen, Carlsbad,
CA) and sodium pyruvate (Invitrogen) at 37 °C and 5% CO
unless otherwise noted.
Recombinant AAV was produced by the two-plasmid
method (Grimm et al., 1998) and purified as described
previously (Zhang et al., 2005). Particle and transducing titers
were determined by real-time PCR using the method and
primers described in (Gigout et al., 2005) or by real-time PCRusing the primers CMV-F (5′-TCAATTACGGGGTCAT-
TAGTT) and CMV-R (5′-ACTAATACGTAGATGTACTGCC).
Dynamitin experiments
HeLa cells were seeded at 4×104 cells/well in a 24-well
plate in growth medium. Cells were transfected with Fugene 6
(Roche Diagnostics, Indianapolis, IN) according to the
manufacturer using 3 μl Fugene 6 and 1 μg of plasmid DNA
per 100 μl OptiMEM (Invitrogen). Forty microliters of the
complexes were used per well. Twenty-four hours after
transfection, the media was aspirated and rAAV2-GFP was
added in fresh growth medium (104 gcp/cell). After an
additional 24 h, dynamitin(p50)-mCherry and GFP expression
were monitored on a FACScalibur (Becton-Dickinson, San
Diego, CA). Tenthousand cells that were a coherent cluster on
the forward and side scatter (FSC/SSC) were collected. The data
were analyzed with Flojo (TreeStar, Ashland, OR). Live cells
were gated based on the FSC/SSC profile. GFP and mCherry
expression percentages were determined by quadrant analysis
(GFP in FL1; mCherry in FL4) with the settings determined by
appropriate single fluorophore controls.
In parallel, immunofluorescence microscopy was performed
by seeding 1.7×104 cells into wells of 8-well Nunc Labtek II
chamber slides. After overnight incubation, transfection was
performed as described above except that only 10 μl of
complexes per well were used. The slides were processed 24 h
later for immunofluorescence microscopy as described below.
Microtubule inhibitor assay
HeLa cells were seeded at 4×104 cells/well in a 24-well
plate in growth medium, incubated over night and pretreated for
4 h with different concentrations of inhibitors at constant
solvent concentrations, 0.5% (v/v). The cells were then
transduced with either single-stranded (104 gcp/cell) or self-
complementary rAAV2 at vector doses ranging between 102
and 104 gcp/cell rAAV2. After incubation for 24 h in presence
of the drug, cells were collected by trypsinization (including
those cells in the supernatant and wash). GFP expression was
analyzed by FACS as follows: after trypsinization, cells were
resuspended in 100 μl 1× binding buffer with 5 μl (0.25 μg) of
7-amino-actinomycin D (7AAD, Annexin V-PE Apoptosis
Detection Kit, BD Pharmingen, San Diego, CA). Cells were
analyzed by FACS after 15 min at room temperature. Viable
cells were defined by their FSC/SSC profiles and, in addition,
their lack of 7AAD staining. GFP+ cells were determined by
comparison with non-transfected control samples. In other
words, to describe the above in order of gating, live cells were
first determined in FSC/SSC as a coherent population. This
population was then analyzed with FL1/FL4 and gated for FL4-
negative cells. The GFP-positive cells are the percentage FL1
positive in this subset (see Fig. S1b). In parallel, immuno-
fluorescence was performed by seeding 1.7×104 cells into
wells of 8-well Nunc Labtek II chamber slides (Rochester, NY),
treated with inhibitors for 4 h and prepared for immunofluor-
escence microscopy as described below.
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After washing with PBS, cells were fixed with 4% para-
formaldehyde in PBS for 20 min and permeabilized with 0.5%
BSA, 0.02% saponin, 0.02% sodium azide in PBS (two-times
20 min). For experiments with p50-mCherry expression, the
Golgi was localized with a monoclonal antibody directed
against the trans-Golgi network protein p230 (BD Transduction
Laboratories, Lexington, KY; 1:100 dilution, 1 h) and a goat-
anti-mouse Alexa Fluor 488 IgG (H+L) (Invitrogen Molecular
Probes, Portland, OR; 1:500 dilution, 30 min). Nuclei were
visualized with DAPI (100 nM).
To analyze the effect of microtubule reorganization, micro-
tubules were visualized with a polyclonal rabbit anti-beta-tubulin
antibody (abcam, Cambridge, MA; 1:200 dilution, 1 h) and a
secondary goat-anti-rabbit Cy2 antibody (Jackson ImmunoR-
esearch,West Grove, PA; 1:200 dilution, 30 min). The Golgi was
localized as described above except that a goat-anti-mouse Cy3
labeled secondary antibody (Jackson ImmunoResearch; 1:400
dilution 30 min) was used. Nuclei were stained with DAPI
(100 nM). Slides were mounted using buffered gelvatol. All
incubations were conducted at room temperature.
The slides were analyzed with a Leica DMRA2 (Leica
Microsystems GmbH, Wetzler, Germany) fluorescence-micro-
scope at 63-fold objective magnification and Hamamatsu
ORCA-ER CCD camera (Opelco, Dulles, VA). Images were
captured using Openlab 5.0.1 (Improvision, Lexington, MA)
and deconvoluted using Volocity 3.6.1 (Improvision).
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